Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Uhl, B; Prochazka, KT; Pansy, K; Wenzl, K; Strobl, J; Baumgartner, C; Szmyra, MM; Waha, JE; Wolf, A; Tomazic, PV; Steinbauer, E; Steinwender, M; Friedl, S; Weniger, M; Küppers, R; Pichler, M; Greinix, HT; Stary, G; Ramsay, AG; Apollonio, B; Feichtinger, J; Beham-Schmid, C; Neumeister, P; Deutsch, AJ.
Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.
Int J Mol Sci. 2022; 23(14):
Doi: 10.3390/ijms23147874
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Deutsch Alexander
- Neumeister Peter
- Uhl Barbara
- Co-authors Med Uni Graz
- Baumgartner Claudia
- Beham-Schmid Christine
- Feichtinger Julia
- Greinix Hildegard
- Pansy Katrin
- Pichler Martin
- Prochazka Katharina
- Tomazic Peter Valentin
- Waha James Elvis
- Wenzl Kerstin
- Wolf Axel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Chemokine receptors and their ligands have been identified as playing an important role in the development of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Richter syndrome (RS). Our aim was to investigate the different expression profiles in de novo DLBCL, transformed follicular lymphoma (tFL), and RS. Here, we profiled the mRNA expression levels of 18 chemokine receptors (CCR1-CCR9, CXCR1-CXCR7, CX3CR1 and XCR1) using RQ-PCR, as well as immunohistochemistry of seven chemokine receptors (CCR1, CCR4-CCR8 and CXCR2) in RS, de novo DLBCL, and tFL biopsy-derived tissues. Tonsil-derived germinal center B-cells (GC-B) served as non-neoplastic controls. The chemokine receptor expression profiles of de novo DLBCL and tFL substantially differed from those of GC-B, with at least 5-fold higher expression of 15 out of the 18 investigated chemokine receptors (CCR1-CCR9, CXCR1, CXCR2, CXCR6, CXCR7, CX3CR1 and XCR1) in these lymphoma subtypes. Interestingly, the de novo DLBCL and tFL exhibited at least 22-fold higher expression of CCR1, CCR5, CCR8, and CXCR6 compared with RS, whereas no significant difference in chemokine receptor expression profile was detected when comparing de novo DLBCL with tFL. Furthermore, in de novo DLBCL and tFLs, a high expression of CCR7 was associated with a poor overall survival in our study cohort, as well as in an independent patient cohort. Our data indicate that the chemokine receptor expression profile of RS differs substantially from that of de novo DLBCL and tFL. Thus, these multiple dysregulated chemokine receptors could represent novel clinical markers as diagnostic and prognostic tools. Moreover, this study highlights the relevance of chemokine signaling crosstalk in the tumor microenvironment of aggressive lymphomas.
- Find related publications in this database (using NLM MeSH Indexing)
- B-Lymphocytes - metabolism
- Germinal Center - metabolism
- Humans - administration & dosage
- Leukemia, Lymphocytic, Chronic, B-Cell - administration & dosage
- Lymphoma, Follicular - genetics, pathology
- Lymphoma, Large B-Cell, Diffuse - pathology
- Neoplasm Recurrence, Local - administration & dosage
- Tumor Microenvironment - administration & dosage
- Find related publications in this database (Keywords)
- diffuse large B-cell lymphoma
- Richter syndrome
- transformed follicular lymphoma
- chemokine receptors
- CCR7
- CCL19
- CCL21